Boosting Antitumour Immunity through Targeted Delivery of Interferon-α

Trends Mol Med. 2019 Nov;25(11):935-937. doi: 10.1016/j.molmed.2019.09.001. Epub 2019 Oct 14.

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionised cancer immunotherapy but their success is wholly dependent on amplifying an existing immune response directed against the tumour. A recent study by Tsuchiya et al. suggests how the properties of induced pluripotent stem cells (iPSCs) may be exploited for the targeted delivery of interferon-α (IFNα) to elicit an appropriate response.

Keywords: dendritic cell; immune checkpoint inhibitors; interferon-α.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Immunotherapy*
  • Interferon-alpha* / metabolism
  • Interferon-alpha* / pharmacology
  • Molecular Targeted Therapy*
  • Neoplasms / immunology*
  • Neoplasms / therapy
  • Pluripotent Stem Cells / immunology
  • Pluripotent Stem Cells / metabolism

Substances

  • Interferon-alpha